DigniCap™ System Chosen for Cancer Patients at BMI Ross Hall Hospital

Clinically-Proven Therapy Prevents Chemo-Related Hair Loss with Greater Comfort
and Precision

~ Glasgow Residents Now Have Access to New State-of-the-Art Cancer Care Therapy
~
LONDON (March 19, 2013)—The DigniCap™ System, considered to be the most
scientifically-advanced scalp-cooling treatment available for reducing
chemotherapy-related hair loss in men and women today, has been chosen by BMI
Ross Hall Hospital in Glasgow as its preferred hair-loss treatment option for
use in its oncology practice. Available now for patients in Glasgow and
surrounding communities, DigniCap is the only system to offer scalp-cooling
above freezing with patented, built-in temperature sensors and a precision
cooling mechanism that allows for gradual and highly tolerable scalp temperature
fluctuations.

The DigniCap™ System, developed by Dignitana, a world leader in scalp-cooling
technology, is a safe, gentle and effective treatment for avoiding hair loss
related to chemotherapy. The system continuously monitors temperature to ensure
comfort and consistent application of the treatment. Caps are specifically
designed so that the ears remain uncovered for added comfort and normal hearing
during the process, and the user-friendly system features an intuitive, touch
-screen control panel.

As the largest private hospital in Glasgow, BMI Ross Hall serves residents from
the south side of Glasgow, across the UK and abroad. Oncologists at BMI Ross
Hall chose to offer the DigniCap ™ System based on its superior tolerability and
efficacy, noting that DigniCap is the first scalp cooling system that can be
offered with clinical evidence, confidence and consistent results at
temperatures above freezing, which makes for a less stressful and much more
comfortable patient experience.

Clinical results show that eight out of ten women in Europe and Asia who used
the DigniCap™ System during chemotherapy retained their hair. Additional trials
at leading medical centers around the world have proven the system to be a
viable alternative for both women and men of diverse ethnicities. Further
clinical results from investigations of the efficacy of scalp cooling with the
DigniCap™ System in both the U.S. and the U.K. will be presented at medical
conferences and in publications throughout 2013.

“BMI Ross Hall Hospital is known throughout Scotland and the UK for its clinical
excellence, state-of-the-art medical innovation and truly compassionate care,”
said Martin Waleij, CEO of Dignitana, maker of the DigniCap™ System. “We are
proud they have chosen to offer their patients the DigniCap™ System—it is an
honour to be able to add BMI Ross Hall in Glasgow to the growing list of top
medical establishments around the world that include the DigniCap™ System in
their comprehensive approach to cancer care.”

Martin Waleij further comments the development of the UK market:

“The order is an initial reference order but we do have have three of the five
largest private healthcare providers as customers and partners. Our aim is to be
a key supplier for the five largest private groups in parallel with becoming a
major contributor of scalp cooling to cancer patients with the public National
Health Service where we currently is working on a mutually beneficial financial
set up for both Dignitana and the NHS trusts”

For more information about the DigniCap™ System offered at BMI Ross Hall
Hospital please email info@bmihealthcare.co.uk.

About BMI Ross Hall Hospital

BMI Ross Hall Hospital in Glasgow is part of BMI Healthcare, Britain's leading
provider of independent healthcare with a nationwide network of hospitals &
clinics performing more complex surgery than any other private healthcare
provider in the country. Our commitment is to quality and value, providing
facilities for advanced surgical procedures together with friendly, professional
care. BMI Ross Hall Hospital has 101 beds with all rooms offering the privacy
and comfort of en-suite facilities, satellite TV and telephone. The hospital has
four theatres, one minor procedures theatre, five bed intensive care unit and a
high dependency unit. These facilities combined with the latest in technology
and on-site support services enable us to undertake a wide range of procedures
from routine investigations to complex surgery. This specialist expertise is
supported by caring and professional medical staff, with dedicated nursing teams
and Resident Medical Officers on duty 24 hours a day, providing care within a
friendly and comfortable environment.

About Dignitana AB (publ)
Dignitana AB, a Swedish medical device company, listed on the OMX Nasdaq First
North Stockholm, focused on the patented DigniCap™ System, a medical device for
preventing hair-loss in chemotherapy patients and for technologies within the
area of medical cooling.

For more information visit www.dignitana.com